Aditya Bagrodia

Yeah, yeah. I would say more early on in my career.

No, I agree. I mean, I think when I was a young hotshot straight out, I was pretty excited. And the data that's kind of seared in my head is that Swarty's eight year biochemical recurrence free rates of about 8%. That kind of killed my enthusiasm. The cases are, are not terrible, not super, you know, you can get some surprise that your orders are tethered in after surgery. And, um,

No, I agree. I mean, I think when I was a young hotshot straight out, I was pretty excited. And the data that's kind of seared in my head is that Swarty's eight year biochemical recurrence free rates of about 8%. That kind of killed my enthusiasm. The cases are, are not terrible, not super, you know, you can get some surprise that your orders are tethered in after surgery. And, um,

No, I agree. I mean, I think when I was a young hotshot straight out, I was pretty excited. And the data that's kind of seared in my head is that Swarty's eight year biochemical recurrence free rates of about 8%. That kind of killed my enthusiasm. The cases are, are not terrible, not super, you know, you can get some surprise that your orders are tethered in after surgery. And, um,

Anyways, but I mean, I think there's might be, if I was going to do it in a highly select motivated patient who's just feels like this is it for them, or maybe radiation is a contraindication. It's really gonna be like we're kicking ADT down the road. And maybe in some post prostatectomy, BCR, radiation. second biochemical recurrence, pelvic node only.

Anyways, but I mean, I think there's might be, if I was going to do it in a highly select motivated patient who's just feels like this is it for them, or maybe radiation is a contraindication. It's really gonna be like we're kicking ADT down the road. And maybe in some post prostatectomy, BCR, radiation. second biochemical recurrence, pelvic node only.

Anyways, but I mean, I think there's might be, if I was going to do it in a highly select motivated patient who's just feels like this is it for them, or maybe radiation is a contraindication. It's really gonna be like we're kicking ADT down the road. And maybe in some post prostatectomy, BCR, radiation. second biochemical recurrence, pelvic node only.

I think you can like have that conversation again to like kick it down the road, but I'm not like very enthusiastic about this anymore. So does that sound okay?

I think you can like have that conversation again to like kick it down the road, but I'm not like very enthusiastic about this anymore. So does that sound okay?

I think you can like have that conversation again to like kick it down the road, but I'm not like very enthusiastic about this anymore. So does that sound okay?

Okay. So we've talked a little bit about when to do it, getting them optimized, PSA levels, earlier is better, that this is a generalization. You're taking into these decisions, the preoperative risk of kind of a bad actor, ADT, nodes, metastasis, directed therapy. I mean, these are going to be multidisciplinary conversations, right? Where you want to have the whole gang in and

Okay. So we've talked a little bit about when to do it, getting them optimized, PSA levels, earlier is better, that this is a generalization. You're taking into these decisions, the preoperative risk of kind of a bad actor, ADT, nodes, metastasis, directed therapy. I mean, these are going to be multidisciplinary conversations, right? Where you want to have the whole gang in and

Okay. So we've talked a little bit about when to do it, getting them optimized, PSA levels, earlier is better, that this is a generalization. You're taking into these decisions, the preoperative risk of kind of a bad actor, ADT, nodes, metastasis, directed therapy. I mean, these are going to be multidisciplinary conversations, right? Where you want to have the whole gang in and

So is there anything about the current kind of state of affairs? And we'll keep it to post-prostatectomy. I mean, I think focal therapy, post-radiation, those are whole separate conversations. I actually did a recent podcast with Amar Kishan on post-radiation, and it was mind-blowing, as always, such a bright guy.

So is there anything about the current kind of state of affairs? And we'll keep it to post-prostatectomy. I mean, I think focal therapy, post-radiation, those are whole separate conversations. I actually did a recent podcast with Amar Kishan on post-radiation, and it was mind-blowing, as always, such a bright guy.

So is there anything about the current kind of state of affairs? And we'll keep it to post-prostatectomy. I mean, I think focal therapy, post-radiation, those are whole separate conversations. I actually did a recent podcast with Amar Kishan on post-radiation, and it was mind-blowing, as always, such a bright guy.

But how about just, you know, for us as good country urologists, urologic oncologists, is there anything that I'm missing here?

But how about just, you know, for us as good country urologists, urologic oncologists, is there anything that I'm missing here?

But how about just, you know, for us as good country urologists, urologic oncologists, is there anything that I'm missing here?

Yeah, I appreciate it. Thanks for kind of hammering the PSMA pet part. I feel like I maybe took that as a foregone conclusion, but it's important to specifically mention that. And I also think it's worth mentioning that if a PSMA pet is negative, that doesn't mean you shouldn't receive treatment necessarily.